Galapagos NV (GLPG)
Market Cap | 1.67B |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | 65.90M |
EPS (ttm) | 0.50 |
PE Ratio | 50.38 |
Forward PE | 81.30 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 100,512 |
Open | 25.13 |
Previous Close | 25.01 |
Day's Range | 25.02 - 25.42 |
52-Week Range | 24.78 - 44.25 |
Beta | 0.04 |
Analysts | Hold |
Price Target | 36.33 (+43.37%) |
Earnings Date | Aug 1, 2024 |
About GLPG
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $36.33, which is an increase of 43.37% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/4/v/press6-2480548.jpg)
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T ...
![](https://cdn.snapi.dev/images/v1/4/b/press7-2454843.jpg)
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc...
![](https://cdn.snapi.dev/images/v1/t/m/press10-2454847.jpg)
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma...
![](https://cdn.snapi.dev/images/v1/w/n/press12-2435963.jpg)
Galapagos creates new subscription right plans
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new su...
![](https://cdn.snapi.dev/images/v1/d/x/press6-2433243.jpg)
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decen...
![](https://cdn.snapi.dev/images/v1/y/q/press18-2407484.jpg)
Galapagos reports first quarter 2024 financial results
Webcast presentation with management on 3 May 2024, at 14:00 CET / 8:00 am ET, www.glpg.com
![](https://cdn.snapi.dev/images/v1/k/x/press18-2401046.jpg)
Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company's Annual and Extraordinary Shareholders' Meetings (AGM ...
![](https://cdn.snapi.dev/images/v1/j/w/press6-2357426.jpg)
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
![](https://cdn.snapi.dev/images/v1/p/w/press13-2347129.jpg)
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings
Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and E...
![](https://cdn.snapi.dev/images/v1/p/k/press10-2342702.jpg)
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Exec...
![](https://cdn.snapi.dev/images/v1/g/p/press6-2289623.jpg)
Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operati...
![](https://cdn.snapi.dev/images/v1/k/z/press17-2279218.jpg)
Galapagos presents at EBMT-EHA annual meeting 2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
![](https://cdn.snapi.dev/images/v1/e/h/press11-2254063.jpg)
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Al...
![](https://cdn.snapi.dev/images/v1/4/l/press17-2217240.jpg)
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (N...
![](https://cdn.snapi.dev/images/v1/r/i/press19-2215406.jpg)
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Bioscience...
![](https://cdn.snapi.dev/images/v1/p/a/press7-2215447.jpg)
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
BridGene Eligible to Receive More Than $700 Million in Potential Upfront and Milestone Payments SAN JOSE, Calif. , Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of...
![](https://cdn.snapi.dev/images/v1/e/0/press3-2212704.jpg)
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotin...
![](https://cdn.snapi.dev/images/v1/o/h/press17-2202571.jpg)
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, e...
![](https://cdn.snapi.dev/images/v1/u/k/press3-2190205.jpg)
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET
![](https://cdn.snapi.dev/images/v1/u/e/press13-2188267.jpg)
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition...
![](https://cdn.snapi.dev/images/v1/h/j/press19-2141273.jpg)
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
Landmark Bio will serve as strategic point-of-care manufacturing partner for Galapagos' CAR-T product candidates in the Boston area WATERTOWN, Mass. , Nov. 6, 2023 /PRNewswire/ -- Landmark Bio, a coll...
![](https://cdn.snapi.dev/images/v1/b/z/press13-2137463.jpg)
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
Webcast presentation tomorrow, 3 November 2023, at 1 3 : 00 CET / 8 :00 am ET, www.glpg.com
![](https://cdn.snapi.dev/images/v1/m/k/press11-2128877.jpg)
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 30 October 2023, 21:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed a letter o...
![](https://cdn.snapi.dev/images/v1/n/i/press3-2070012.jpg)
Galapagos appoints Simon Sturge to its Board of Directors
Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of Directors appointed Mr. Simon Stur...
![](https://cdn.snapi.dev/images/v1/g/r/press6-2040140.jpg)
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Mechelen, Belgium; 28 August 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in GALACELA, a Phase 2 systemic lupus erythematosus (SLE) tr...